Related Experiment Video
Updated: Jun 28, 2026
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
Recent advances in biliary atresia: prospects for novel therapies
Barbara A Haber1, Jessi Erlichman, Kathleen M Loomes
1Associate Professor of Pediatrics The Childrens Hospital of Philadelphia, Division of GI, Hepatology & Nutrition, Philadelphia, PA 19104, USA. haber@E-mail.chop.edu
Insights
Biliary atresia (BA) is a fatal liver disease in infants. Current palliative treatments offer limited success, highlighting the need for novel therapies targeting inflammation and fibrosis to improve outcomes.
Area of Science:
- Pediatric Hepatology
- Gastroenterology
- Neonatal Medicine
Background:
- Biliary atresia (BA) is a severe, progressive fibro-obliterative liver disease affecting the extrahepatic biliary tree in infants.
- Early diagnosis before two months of age is critical, as untreated BA is fatal.
- Current treatments are palliative, focusing on supportive care and managing complications, with only 50% of patients remaining transplant-free by age two.
Purpose of the Study:
- To review existing literature on current treatment strategies for biliary atresia.
- To explore potential future therapeutic targets and interventions for BA.
Main Methods:
- Comprehensive literature review of biliary atresia care.
- Analysis of nuances in diagnosis, nutritional support, and sequelae management.
- Examination of emerging therapeutic concepts.
Main Results:
- Current therapies for biliary atresia are primarily palliative and do not alter the disease's natural progression.
- Limited success rates indicate a significant unmet need for more effective treatments.
- The review synthesizes information on supportive care and interventions for BA complications.
Conclusions:
- Improved outcomes for biliary atresia necessitate the development of novel therapeutic approaches.
- Future treatments should aim to target the underlying inflammatory and fibrotic processes of the disease.
- Intervention in these key pathological steps holds promise for significantly enhancing patient prognosis.
Background:
Biliary atresia (BA) is a progressive fibro-obliterative disease of the extrahepatic biliary tree that presents with biliary obstruction before 2 months of age. Untreated BA is a uniformly fatal disease and even with our current therapies only 50% of children with BA will be transplant-free by 2 years of age. Despite descriptions of this disorder dating back to the 1800s our current therapies are palliative. They focus on prompt diagnosis, supportive nutritional care and interventions for sequelae.
Objective:
To present the literature supporting current treatment strategies and potential future therapies.
Method:
Each of the aspects of care is described and the literature about nuances of care is provided.
Conclusion:
Therapies will not improve outcomes until novel treatments are introduced, such as those suggested, which may intervene in the inflammatory or fibrotic steps of the disease process.